Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01547143

Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis — HELA2012  

Hemophagocytic Lymphohistiocytosis Clinical Trial

Official title:
Pilot Study of First-line Immunosuppressive Therapy Combined With Etoposide and Allogeneic Hematopoietic Cell Transplantation in Refractory/Reactivated Cases for Hemophagocytic Lymphohistiocytosis (HLH) in Adult Patients

Clinical Trial Summary

The investigators would like to propose a pilot study evaluating the efficacy of etoposide combined with immunosuppressive agents for adult secondary hemophagocytic lymphohistiocytosis (HLH), in order to prove out whether the modification of previous HLH-94 or HLH-2004 protocol for childhood patients can improve the outcome and decrease the toxicities. The results of this pilot study will be a base of a more-improved phase-2 protocol.

Clinical Trial Description

The treatment of HLH in adult patients has not been determined yet. Actually, we adopted the treatment protocol HLH2004, which was developed for pediatric HLH patients. The HLH2004 protocol, which is a potent and successful treatment for HLH, has shown some limitations in the treatment of adult HLH. First, the dose of etoposide is somewhat high for adult patients to tolerate. Second, the high incidence of opportunistic infection such as fungal, bacterial, and viral has threatened the patients. Third, more aggressive and intensive approach to adopt allogeneic hematopoietic cell transplantation will be needed earlier in adult patients. Based on these rationales, we developed a modified protocol based on HLH2004 to pit the treatment of adult HLH patients. ;

Study Design

Related Conditions & MeSH terms

  • Hemophagocytic Lymphohistiocytosis
  • Lymphohistiocytosis, Hemophagocytic
Clinical Trial Details
NCT number NCT01547143
Study type Interventional
Source Asan Medical Center
Contact
Status Terminated
Phase N/A
Start date March 2012
Completion date May 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Recruiting NCT02912702 - L-DEP as an Initial Treatment for EBV-HLH Phase 3
Terminated NCT00176826 - T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Phase 2/Phase 3
Not yet recruiting NCT06038422 - GTP Regimen in the Treatment of Refractory/Recurrent HLH Phase 3
Completed NCT03510650 - Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
Completed NCT03259230 - Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
Active, not recruiting NCT01494103 - Administration of Donor T Cells With the Caspase-9 Suicide Gene Phase 1
Recruiting NCT05164978 - DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Active, not recruiting NCT00006056 - Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Recruiting NCT03795909 - Ruxolitinib Combined With Dexamethasone for HLH Phase 1/Phase 2
Recruiting NCT03533790 - DEP-Ru Regimen as a Salvage Therapy for HLH Phase 3
Not yet recruiting NCT05315336 - L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH Phase 3
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting NCT04326348 - A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH） Phase 1
Recruiting NCT04551131 - Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis Phase 1/Phase 2
Recruiting NCT05546060 - Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH Phase 1
Recruiting NCT05137522 - Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH N/A
Recruiting NCT04120090 - Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis Phase 3